Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West Pharmaceutical Services reported a strong Q3 2021, with net sales of $706.5 million, a 28.9% increase year-over-year. Reported diluted EPS rose 112% to $2.31. The company raised its full-year net sales guidance to $2.800-$2.810 billion and adjusted diluted EPS guidance to $8.40-$8.50. A quarterly dividend of $0.18 per share was approved, reflecting a 5.9% increase. Sales growth was driven by proprietary products, particularly from the High-Value Product portfolio.
Summary not available.
West Pharmaceutical Services announced the launch of its DeltaCube™ Modeling Platform and NovaGuard® SA Pro Safety System for 0.5mL Standard Glass Syringes at Interphex from October 19-21 in New York. The DeltaCube™ platform aids in vial integrity modeling, enhancing decision-making in container closure systems. The NovaGuard® SA Pro system expands product offerings for pre-filled syringes, addressing safety with innovative features to protect against needlestick injuries. This initiative reflects a strategic response to market demands for safer and more efficient drug delivery solutions.
West Pharmaceutical Services (NYSE: WST) will announce third-quarter 2021 financial results on October 28, 2021, before market opening. A conference call will take place at 9:00 a.m. Eastern Time to discuss the results and future business outlook. Interested participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 5587559. The event will be streamed live on the company's website, with an archived version available afterward until November 4, 2021.
West Pharmaceutical Services (NYSE: WST) has appointed Molly Joseph to its Board of Directors, expanding the board to 11 members. Joseph, 47, previously served as CEO of UnitedHealthcare Group for over a decade, where she led the development of a significant global health business. Her experience includes oversight of extensive medical facilities and strategic corporate development. With her extensive healthcare and board experience, the company anticipates that her expertise will enhance its mission in delivering healthcare solutions worldwide.
West Pharmaceutical Services reported a strong second quarter in 2021, with net sales of $723.6 million, a growth of 37.3%. Organic sales growth was 30.6%, and diluted EPS rose to $2.47, marking a 104% increase. The company raised its full-year 2021 net sales guidance to $2.760-$2.785 billion and adjusted-diluted EPS guidance to $8.05-$8.20. The growth was driven by demand for high-value product components, particularly related to COVID-19 vaccines. Operating cash flow reached $233.1 million, reflecting a 13.6% increase.
West Pharmaceutical Services (NYSE: WST) will announce its second-quarter 2021 financial results on July 29, 2021, prior to market opening. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time featuring a discussion on results and business outlook. Interested participants can join the call by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 3089097. An online archive will be accessible on the company’s website for future reference.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 PM ET. A live broadcast of the event can be accessed on their website in the 'Investors' section. West has nearly 10,000 employees across 50 locations and generated over $2.15 billion in sales in 2020. The company is a trusted partner to drug developers, delivering over 40 billion components annually.
West Pharmaceutical Services has declared a third-quarter 2021 dividend of $0.17 per share, scheduled for payment on August 4, 2021, to shareholders recorded as of July 21, 2021. This dividend reflects the company's ongoing commitment to return value to its shareholders. Additionally, management will present a business overview at the Bank of America Securities 2021 Healthcare Conference on May 11, 2021, at 2:45 p.m. EDT. West generated over $2.15 billion in sales in fiscal year 2020.
West Pharmaceutical Services reported impressive Q1 2021 results with net sales of $670.7 million, a 36.5% year-over-year increase. Diluted EPS rose 101% to $1.99, while adjusted-diluted EPS climbed 103% to $2.05. The company has raised its full-year net sales guidance to $2.630 billion - $2.655 billion from a previous range of $2.500 billion - $2.525 billion. This growth is attributed to strong organic sales driven by demand for COVID-19 related products and robust performance in the Proprietary Product Segment.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
